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ABSTRACT
Bonemineral density(BMD)measuredatthe femoral neck(FN)isthemost important riskphenotypeforosteoporosis andhasbeen used
as a reference standard for describing osteoporosis. The specific genes influencing FN BMD remain largely unknown. To identify such
genes,wefirstperformed agenome-wideassociation(GWA)analysisforFNBMDinadiscoverysampleconsistingof983unrelatedwhite
subjects. We then tested the top significant single-nucleotide polymorphisms (SNPs; 175 SNPs with p<5 10
 4) for replication in a
family-based sample of 2557 white subjects. Combing results from these two samples, we found that two genes, parathyroid hormone
(PTH) and interleukin 21 receptor (IL21R), achieved consistent association results in both the discovery and replication samples. The PTH
gene SNPs, rs9630182, rs2036417, and rs7125774, achieved p values of 1.10 10
 4, 3.24 10
 4, and 3.06 10
 4, respectively, in the
discoverysample; pvaluesof6.50 10
 4,5.08 10
 3,and5.68 10
 3, respectively,inthe replicationsample;andcombined pvaluesof
3.98 10
 7, 9.52 10
 6, and 1.05 10
 5, respectively, in the total sample. The IL21R gene SNPs, rs8057551, rs8061992, and rs7199138,
achievedpvaluesof1.51 10
 4,1.53 10
 4,and3.88 10
 4,respectively,inthediscoverysample;pvaluesof2.36 10
 3,6.74 10
 3,
and 6.41 10
 3, respectively, in the replication sample; and combined p values of 2.31 10
 6, 8.62 10
 6, and 1.41 10
 5,
respectively, in the total sample. The effect size of each SNP was approximately 0.11 SD estimated in the discovery sample. PTH
and IL21R both have potential biologic functions important to bone metabolism. Overall, our findings provide some new clues to the
understanding of the genetic architecture of osteoporosis.  2010 American Society for Bone and Mineral Research.
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Introduction
O
steoporosis is a serious public health problem associated
with substantive morbidity and mortality,
(1) as well as
tremendous health care expenditures.
(2) It is a common disease
characterized by low bone mass and increased risk of fragility
fractures. Clinically, bone mineral density (BMD) is the single best
predictor of osteoporotic fractures.
(3,4) Since hip fracture is the
most common and severe form of osteoporotic fractures, and
since the risk of hip fracture increases 2.6-fold for each standard
deviation (SD) decrease in BMD measured at the femoral neck
(FN), low FN BMD is the most important risk factor for
osteoporosis at the hip and has been used widely as a reference
standard for the description of osteoporosis.
(5)
FN BMD is a highly heritable quantitative trait, with estimated
heritability over 75%.
(6,7) Numerous association or linkage
analyses have been conducted to identify candidate genes for
BMD, although only a few genes were well replicated, such as
ESR1, COL1A1, VDR, LRP5, OPG, and CYP19A1.
(8–16) Recent
advances in single-nucleotide polymorphism (SNP) genotyping
technologies and analytical methods have provided new
opportunities for researchers to launch powerful genome-wide
association (GWA) studies to discover common variants for BMD
that have yielded certain results.
(13,14,17,18) However, the variants
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1042identified by the previous genetic studies could explain, in
combination, only a very small fraction (<10%) of the BMD
variation. This means that many additional genetic variants
underlying BMD have to be uncovered. Therefore, we performed
a GWA study to identify novel genetic variants that may
influence FN BMD.
Materials and Methods
Subjects
This study was approved by the required institutional review
board or research administration of the involved institutions.
Signed informed-consent documents were obtained from all
study participants before entering the study. The basic
characteristics of the study sample sets are summarized in
Table 1, with additional descriptions below.
Discovery Sample
Thediscoverysamplesetwasidentifiedfromourestablishedand
expanding database currently containing more than 10,000
subjects.This sampleconsisted of983unrelated healthysubjects
(495 women and 488 men) who had both the phenotype and
genotype information. All the subjects were white US citizens of
northern European origin living in Omaha, Nebraska, and its
surrounding regions in the Midwest. Subjects with chronic
diseases and conditions that potentially might affect bone mass,
structure, or metabolism were excluded from the study to
minimize the influence of known environmental and therapeutic
factors on bone variation. The exclusion criteria have been
detailed in an earlier publication.
(19) BMD measurements were
obtained using dual-energy X-ray absorptiometry (DXA; Hologic
QDR4500, Hologic Inc., Waltham, MA, USA) at the FN. The
coefficient of variation (CV) value of the FN BMD was
approximately 1.40%.
Replication Sample
The replication sample was derived from the Framingham Heart
Study(FHS) SNPHealth Association Resource (SHARe) Project, for
which genotyping was conducted in over 9300 phenotyped
subjects from three generations (including over 900 families).
Details about and descriptions of the FHS were reported
previously.
(20,21) We have the data on 2557 phenotyped white
subjects from 750 families. In this group, 841 subjects (325 men
and 516 women) were from the original cohort, and 1716 (823
men and 893 women) were from the offspring cohort. The
original cohort participants had BMD measures by DXA machine
(Lunar DPX-L, Lunar Corp., Madison, WI, USA) at the FN
performed at examination number 22. The offspring cohort
participants were scanned with the same machine at examina-
tion 6 or 7. As reported previously,
(21) the CV was 1.7% for FN.
Genotyping and quality control
For the discovery sample, genomic DNA was extracted from
whole human blood using a commercial isolation kit (Gentra
Systems, Minneapolis, MN, USA) following the standard protocol.
Genotyping was carried out at Vanderbilt Microarray Shared
Resource using the Affymetrix Human Mapping 500K array set
(Affymetrix, Santa Clara, CA, USA), as described in a previous
publication.
(22) The final average Bayesian Robust Linear Model
with Mahalanobis distance classifier (BRLMM)
(23) call rate across
the entire sample reached a high level of 99.14%. However, of
the initial full setof500,568 SNPs,wediscarded 32,961 SNPswith
call rate of less than 95%, another 33,358 SNPs deviating from
Hardy-Weinberg equilibrium (HWE; p<.0001), and 91,395 SNPs
with minor allele frequencies (MAFs) of less than 5%. Therefore,
the final analyses were restricted to 342,854 SNPs.
For the replication sample, genotyping was performed using
approximately 550,000 SNPs (Affymetrix 500K mapping array
plus Affymetrix 50K supplemental array). For details of the
genotyping method, please refer to the FHS SHARe at the NCBI
dbGaP Web site (www.ncbi.nlm.nih.gov/projects/gap/cgibin/
study.cgi?study_id¼phs000007.v3.p2). The quality control was
the same as that adopted for the discovery sample by excluding
SNPs with a call rate of less than 95%, deviating from HWE
(p<.0001), and with MAFs of less than 5%. There were 386,731
SNPs available for subsequent analyses.
Statistical analysis
The raw BMD values were adjusted by the significant covariates,
including age, sex, and weight. The BMD residuals were used for
subsequent association analyses. For the discovery sample,
EIGENSTRAT
(24) was applied to test for SNP associations,
assuming an additive inheritance model. The first 10 principal
components were selected to perform such analyses. For the
follow-up replication sample, we selected the most significantly
Table 1. Summary Characteristics of the Study Subjects
Discovery sample Replication sample Total sample
Number assessed for BMD 983 2557 3540
Gender (males/females) 488/495 1148/1409 1636/1904
Age (years) 50.3 (18.3) 66.4 (11.6) 62.0 (15.6)
Weight (kg) 80.1 (17.7) 76.4 (17.3) 77.4 (17.5)
Height (cm) 170.8 (9.7) 165.5 (10.2) 167.0 (11.1)
Femoral neck BMD (g/cm
2) 0.81 (0.14) 0.87 (0.17) 0.86 (0.16)
Note: Data are shown as mean (SD).
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 4 (175 SNPs) to test
for associations with FN BMD. FBAT
(25) was used to examine
family-based associations under the additive model.
Meta-analysis statistics were generated using the weighted
Z-scores (a standard normal deviate, the statistic associated
with a p value) to quantify the overall evidence for association
with BMD. The individual Z-score was weighted by the square
root of the sample size of each study. We added the individual
weighted Z-scores derived from each sample together and
divided by the square root of the sum of the sample sizes to
obtain anoverall Z-scoreand an associated combined p value.
(26)
Combining results from all sample sets by meta-analysis, we
set the threshold for genome-wide significance at p<4.2 10
 7
according to Freimer and Sabatti
(27) and Lencz and collea-
gues,
(28) who preferred a more accurate estimate by considering
the total number of genes in the human genome. Moreover, a
nominally significant association threshold (p<.05) was set in
the replication stage to ensure that the overall significant
association is robust across populations.
Haploview Version 4.1
(29) was used to characterize linkage
disequilibrium (LD, r
2) pattern and plot the haplotype block
patterns.
Different genotyping platforms were used in our GWA study
and in previous BMD GWA studies.
(13,14,17) For those reported
promising SNPs that were missing in our Affymetrix 500K arrays,
we imputed the genotypes using the IMPUTE program
(30) in
order to facilitate comparison of associations at the same SNPs.
To ensure the reliability of the imputation, all the imputed SNPs
have reached a calling threshold of 0.90, i.e., a 90% probability
that an imputed genotype is true. SNPTEST
(30) was used to test
for associations between the imputed SNPs and FN BMD using
age, sex, and weight as covariates.
Results
We first carried out a GWA scan in the discovery sample of 983
unrelated white persons and then selected the top 175 most
significantly associated SNPs with p<5 10
 4 (Supplemental
Table 1) to test for associations in the replication sample of
2557 white persons from 750 families. Combining results from
these two sample sets, we identified two promising loci, 11p15
and 16p11, that harbored a cluster of 6 SNPs ranked as the
most significant SNPs among the list (Table 2). 11p15 was
represented by three significant SNPs, which were rs9630182
(combined p¼3.98 10
 7), rs2036417 (combined p¼9.52 
10
 6), and rs7125774 (combined p¼1.05 10
 5), respectively.
In particular, rs9630182 achieved the genome-wide signifi-
cance level (p<4.2 10
 7) .T h e s et h r e eS N P sa r eh i g h l y
correlated with one another (pairwise LD r
2>0.99; Fig. 1A)a n d
are located approximately 100kb upstream of the parathyroid
hormone (PTH) gene. The whole PTH gene, including these
three SNPs (from upstream to downstream), was localized to a
single block with a size of 125kb (Fig. 1A). This gene has been
reported previously to be a potent modulator to regulate
osteoblasts and to increase bone formation.
(31,32) This is
consistent with our findings that these three SNPs have a
consistently protective effect on BMD because each copy of
the minor allele of each SNP was associated with an increase in
FN BMD by approximately 0.11 SD, as estimated in the
discovery sample. The effect of each SNP in the replication
sample was in the same direction as in the discovery sample.
The variance in BMD variation explained by these three
SNPs was 1.64% (rs9630182), 1.52% (rs2036417), and 1.38%
(rs7125774), respectively. We also compared the distribution
differences of genotype frequencies for the identified SNPs
between the two studied samples and found no significant
differences (p>.05) (Supplemental Table 2).
Anotherpromisingloci,16p11,containsthreesignificantSNPs,
rs8057551 (combined p¼2.31 10
 6), rs8061992 (combined
p¼8.62 10
 6), and rs7199138 (combined p¼1.41 10
 5).
Although these three SNPs did not reach genome-wide
significance, they are clustered in a potential candidate gene,
interleukin 21 receptor (IL21R). This gene is a cytokine receptor
that is important to bone biology. The three SNPs are in strong
LD with each other (r
2>0.95) and are located in an LD block
within intron 1 of IL21R (Fig. 1B). All three of these SNPs were
associated with an increasedFN BMD valuein boththe discovery
and the replication samples, with the effect size estimated to be
approximately 0.11 SD for each minor allele of each SNP in the
discovery sample. The contribution of the three SNPs to BMD
variation was 1.47% (rs8057551), 1.40% (rs8061992), and 1.22%
(rs7199138), respectively.
Table 2. Associations Between SNPs at the Two Promising Regions for BMD at the Femoral Neck
SNP Position Alleles
a
Discovery sample Replication sample
Combined p value MAF p Value Effect size (SD)
b MAF p Value
11p15 (PTH)
rs9630182 13576748 T/C 0.345 1.10 10
 4 0.1104 0.383 6.50 10
 4 3.98 10
 7
rs2036417 13574184 A/G 0.364 3.24 10
 4 0.1101 0.386 5.08 10
 3 9.52 10
 6
rs7125774 13575380 C/T 0.357 3.06 10
 4 0.1100 0.381 5.68 10
 3 1.05 10
 5
16p11 (IL21R)
rs8057551 27342428 G/A 0.325 1.51 10
 4 0.1102 0.317 2.36 10
 3 2.31 10
 6
rs8061992 27342539 A/C 0.335 1.53 10
 4 0.1101 0.312 6.74 10
 3 8.62 10
 6
rs7199138 27342034 C/G 0.335 3.88 10
 4 0.1103 0.315 6.41 10
 3 1.41 10
 5
aThe former allele represents the minor allele.
bEffect size is the additive effect of each minor allele on the residual of femoral neck BMD (after adjustment for age, sex, and weight).
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(adjusted for age and weight) for the preceding 6 SNPs in PTH
and IL21R. The significant associations in the total sample could
be generally replicated in each gender group (Table 3). For PTH,
the associations were driven mainly by male subjects, whereas
for IL21R, the associations were caused mainly by female
subjects, as reflected in the discovery sample. Overall, the
association signals in each gender group generally were weaker
than in the total sample, which might be largely due to the
smaller sample sizes in each gender group.
Using the genotyped and imputed genotypes in our GWA
discovery sample of 983 unrelated white persons, we examined
the associations between FN BMD and the key SNPs identified in
previous GWA studies.
(13,14,17) Five SNPs were confirmed to be
associated with FN BMD in our sample, including rs851982
(p¼.012) and rs4870044 (p¼.045) in ESR1, rs6469804 (p¼.030)
in OPG, rs3736228 (p¼.048) in LRP5, and rs2010281 (p¼.048) in
MARK3 (Table 4). Moreover, another two new SNPs in LRP5 also
were found to be associated with FN BMD in our sample (i.e.,
rs604944, p¼5.3 10
 4, and rs4988327, p¼3.6 10
 3). Mean-
while, for SNPsthat werenot confirmed inour sample, welist the
results in Supplemental Table 3 for reference.
Discussion
The GWA approach is a state-of-the-art approach to uncover
modest genetic variants contributing to common diseases or
phenotypes. Using a GWA approach, our group has reported
two candidate genes—ADAMTS18 (16q23) and TGFBR3
(1p22)—for spine or hip BMD previously.
(18) In addition, three
other GWA studies on BMD have been published,
(13,14,17) and
they successfully identified several candidate genes for BMD,
including RANKL (13q14), OPG (8q24), RANK (18q21), ESR1 (6q25),
LRP5 (11q13), SOST (17q21), MARK3 (14q32), and SP7 (12q13).
However, these loci in combination can explain only a small
fraction of BMD variation, leaving the majority of the genetic
factors that influence BMD variation unknown. In addition, most
published GWA studies focused only on the genes or SNPs of
top-ranking statistical significance, which may ignore some
useful information. In this study, by using available GWA data
sets from two white populations, we identified two susceptibility
genes—PTH (11p15) and IL21R (16p11)—associated with FN
BMD variation. These two genes were not in the top-significance
list in either of the populations and were not identified by our
previous GWA study on BMD.
(18) However, combining the
two data sets by meta-analysis revealed the promising
significance of these two genes because the meta-analysis
could improve the power to detect more associations and
investigate the consistency of those associations across different
populations.
(33) Moreover, both genes have potential biologic
functions that are important to bone metabolism. Thus our
findingsaddedmore informationtotheoverallunderstanding of
the genetic basis of osteoporosis.
Fig. 1. Pair-wise linkage disequilibrium diagrams for two promising loci: (A) PTH;( B) IL21R. Pair-wise linkage disequilibrium (LD), measured as r
2, was
calculatedfromgenotypingdatainthediscoverysampleusingtheHAPLOVIEWprogram.Shadingrepresentsthemagnitudeofpair-wiseLD,withawhite-
to-black gradient reflecting lower to higher LD values. The scatter graph indicates the negative logarithm of p value for each SNP in the discovery sample.
The x axis denotes the genomic position.
Table 3. Gender-Specific Association Signals for the Six SNPs
Identified for BMD at the Femoral Neck
SNP
Discovery sample
p value
Replication sample
p value
Male Female Male Female
11p15 (PTH)
rs9630182 3.56 10
 4 0.051 5.11 10
 3 0.022
rs2036417 3.88 10
 4 0.121 0.026 0.062
rs7125774 5.06 10
 4 0.059 0.032 0.046
16p11 (IL21R)
rs8057551 0.010 5.60 10
 3 0.020 0.034
rs8061992 0.011 6.37 10
 3 0.034 0.055
rs7199138 0.021 9.35 10
 3 0.032 0.048
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remodeling. In experimental animals and patients with osteo-
porosis, intermittent administration of PTH can increase bone
mass by stimulating de novo bone formation.
(32,34–36) However,
genetic studies testing for association between polymorphisms
in PTH and osteoporosis are lacking, and most of them are
underpowered and show inconsistent results.
(37–41) Our study
found a consistent association between PTH and FN BMD in two
independent white populations, thereby supporting the con-
clusion that PTH is an important candidate gene for BMD and
osteoporosis. Although the significant SNPs we identified are
locatedintheupstreamofthePTHgene,theyareclusteredinthe
same LD block as the SNPs within the PTH gene. In addition,
intergenic transcription now has been recognized as an active
and common cellular process. Extensive transcription has been
observed in unannotated genomic regions that are related to
genotype-phenotype correlations.
(42,43) As an important func-
tion, intergenic transcription can regulate expression of the
nearby genes.
(44,45) In particular, SNPs rs9630182 and rs2036417
are located at potential transcription factor binding sites
predicted by the FASTSNP program (http://fastsnp.ibms.sinica.
edu.tw). Thus we hypothesized that those SNPs potentially
might regulate PTH gene expression through intergenic trans-
cription, although the real molecular mechanisms await further
investigation.
Cytokins are potent mediators regulating homeostasis of the
immune system and pathophysiologic processes. As a member
of the type I cytokine receptors, IL21R has multiple functions. For
example, IL21R plays an important role in the proliferation and
differentiation ofvarious immunecells, suchas T cells andBcells.
Studies have shown that B cells may participate in osteoclas-
togenesis.
(46) IL21R induces the growth-promoting signals of its
ligand, IL21, which might be involved in the maturation and
functionofmyeloidcells.
(47)IL21RandIL21havebeenrevealedto
be involved in a variety of human diseases, including cancers,
inflammatory bowel disease and Crohn’s disease, and multiple
autoimmune diseases. Especially, IL21R has been identified as
associated with the activated phenotype of rheumatoid arthritis
fibroblasts and correlates negatively with the destruction of
cartilage and bone.
(48) With this information taken together, we
suggested that IL21R may be a new candidate gene for BMD.
We compared the results for the key SNPs identified in
previous BMD GWA studies
(13,14,17) with our current GWA study.
Since replication analysis was the specific hypothesis driven,
p<.05wasconsideredsignificant.Weconfirmedassociationsfor
several SNPs located in the previously well-studied candidate
genes, such as ESR1, OPG, and LRP5 (Table 4). However, some
SNPs were not able to be replicated in our study (Supplemental
Table 3), which might be affected by many factors. First, the
effect sizes of variants were very small and thus easily lead to
failure of replication under current statistical power. Second,
some SNPs identified in previous studies were for spine BMD,
and our study focused only on FN BMD. BMDs at different
skeletal sites may have different genetic mechanisms. Third, the
differences in gene-gene and gene-environment interactions
between the two study sets may result in inconsistency in
replication. In addition, other factors, such as differential LD and
allele frequencies across populations, also may significantly
influence the chance of replicating GWA results.
It is worth emphasizing that population stratification is
unlikely to be a major concern in this GWA study. This is so
first because we used EIGENSTRAT to perform GWA analyses in
the discovery sample, which can control for potential population
stratification effectively. Second, we used a family-based sample
to perform replication analyses. Family-based samples are ideal
for the follow-up validation of initial GWA findings
(49) because
they are robust to population stratification and essentially can
eliminate the possible impact of population stratification. Thus
our GWA results are not likely to be plagued by spurious
associations owing to population stratification.
In summary, we identified two susceptibility bone mass
candidate genes, PTH and IL21R, that may influence FN BMD
variation. Although additional functional studies are required to
elucidate the detailed roles and potential functional variants of
these loci, our findings provide some new insights into the
understanding of the genetic architecture of BMD and
osteoporosis.
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Table 4. Comparison of the Previous GWA Studies for BMD and the Current GWA Study
SNP
Associated
gene Cytoband
Current GWA
p value Published GWA p value
a Reference
rs851982 ESR1 6q25 0.012 1.6 10
 5 (hip BMD
b)1 4
rs4870044 ESR1 6q25 0.045 9.9 10
 5 (hip BMD) 14
rs6469804 OPG 8q24 0.030 1.6 10
 4 (SPBMD
c)1 3
0.04 (hip BMD) 14
rs3736228 LRP5 11q13 0.048 1.9 10
 5 (SPBMD) 13
rs604944 LRP5 11q13 5.3 10
 4 —
rs4988327 LRP5 11q13 3.6 10
 3 —
rs2010281 MARK3 14q32 0.023 7.4 10
 5 (hip BMD) 17
ap value reported here was the original P value in the discovery sample in each GWA study.
bHip BMD is the combined BMD at the femoral neck, trochanter, and intertrochanter region.
cSPBMD¼spine BMD.
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